BNET Industries
Merck & Co. Inc. (MRK) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $24.1B
- Profit
- Dec 31 2007
- $3.2B
- Market Cap
- May 14 2008
- $85.4B
Latest News and Analysis
Takeda Sees Big Profit Slump on Millennium Costs
By Edwina Gibbs TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 77 percent drop in quarterly operating profit as it spent to boost its pipeline, and forecast a sharp fall in annual income linked to the costs of its $8...
Drugmakers Need to Rein in Ads, Hearing Told
By Susan Heavey WASHINGTON (Reuters) - Pharmaceutical companies need to be more responsible in touting products to consumers or else face tighter controls from Congress, a top U.S. Democratic lawmaker said on Thursday. Rep. Bart Stupak, at a hearing to discuss specific ads...
Schering-Plough Now in the Feds' Crosshairs
The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
Medtronic to Cut About 1,100 Jobs
By Susan Kelly CHICAGO (Reuters) - Medtronic Inc MDT on Tuesday said it would eliminate about 1,100 jobs this year, or almost 3 percent of its work force, in businesses whose growth has slowed, including its flagship heart rhythm device unit. The company...
Man Bites Dog: Former Merck CEO Blasts High Drug Prices
Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
Pfizer Reaches Deal With Some Celebrex Users: Report
NEW YORK (Reuters) - Pfizer Inc PFE has reached tentative deals with some patients who claim to have suffered heart attacks and strokes from taking the company's Celebrex and Bextra pain medicines, the Wall Street Journal said on Friday, citing plaintiff...
Merck Extends Deadline For Vioxx Settlement
NEW YORK (Reuters) - Merck & Co MRK said on Thursday at least 94 percent of eligible U.S. claimants have elected to participate in its $4.85 billion proposed Vioxx settlement, and the drugmaker extended the deadline for the remainder to join ...
FDA to New Drugs: It's Hammer Time
Wonder no further whether the recent litany of drug-safety problems would make the Food and Drug Administration more cautious about approving new drugs. In just the past four days, the agency has thrown some serious sand into the industry's drug-development works, delaying or derailing three separate programs of widely varying...
Cholesterol-drug Rejection Rips New Gash in Merck
By Ransdell Pierson NEW YORK (Reuters) - Confidence in Merck & Co's MRK earnings prospects withered on Tuesday, along with its stock price, after U.S. regulators surprisingly rejected the drugmaker's treatment to raise levels of "good" HDL cholesterol. Shares of Merck,...
Is Merck Hanging Schering Out to Dry on Vytorin?
A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
Schering Shares Jump After Profit Beats Forecasts
By Ransdell Pierson NEW YORK (Reuters) - Schering-Plough Corp SGP, whose stock has been battered this year by a failed trial of its Vytorin cholesterol drug, reported a quarterly profit well above Wall Street forecasts thanks to cost controls, lifting its...
Costs Help Merck and Novartis, Hit Lilly
By Bill Berkrot NEW YORK (Reuters) - Tight cost controls helped Merck & Co MRK and Swiss drugmaker Novartis AG NOVN to better-than-expected quarterly earnings on Monday, while high expenses contributed to disappointing results from Eli Lilly and Co LLY. Lilly...
Pfizer Profit Misses Mark
By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Pfizer Inc PFE on Thursday reported a worse-than-expected drop in quarterly earnings due to higher expenses and plunging U.S. sales of its cholesterol fighter Lipitor, sending its shares down almost 4 percent. The...
Abbott Profit Up on Drugs Sales
By Ransdell Pierson NEW YORK (Reuters) - Abbott Laboratories Inc ABT said on Wednesday first-quarter earnings increased 34 percent on higher sales of its prescription drugs and medical devices and favorable foreign exchange factors. The company reported strong sales gains for its top...
How Pharma Stacks the Deck with Medical Journals
Some once-friendly ghosts may be getting Merck in trouble all over again. The ethereal beings in question are ghostwriters -- the nameless, faceless freelancers paid by drug companies to draft up medical review papers, usually well before they're even seen by the academic researchers who will eventually...
Merck, Schering Unable to Stop Digging in Vytorin Mess
As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- David P. Hamilton (10 results)
- Sales Strategy (9 results)
- Sales (9 results)
- Vytorin (8 results)
- Schering-Plough Corp. (5 results)
- E-mail (5 results)
- Online Communications (5 results)
- Pharmaceutical Company (4 results)
- Sales Force Management (4 results)
- Pfizer Inc. (3 results)
- Healthcare (3 results)
- Abbott Laboratories Inc. (3 results)
- Johnson & Johnson (3 results)
- Drug (3 results)
- Schering (3 results)
- Marketing (3 results)
- FDA (3 results)
- Incorporated: 1927
- CEO: Mr. Richard T. Clark
Merck & Co. is a pharmaceutical company engaged in discovering, developing, producing and marketing products designed to improve human and animal health, directly and through joint ventures. Co.'s products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Among these are Singulair (montelukast sodium), a leukotriene receptor antagonist for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis; Cozaar (losartan potassium), Hyzaar (losartan potassium and hydrochlorothiazide); Fosamax (alendronate sodium) and Fosamax Plus D (alendronate sodium/cholecalciferol).
Key Competitors
Merck & Co. Inc. Company Info
Board of Directors
Mr. Richard T. Clark
Chairman
Ms. Anne M. Tatlock
Dr. Samuel O. Thier M.D.
Mr. Peter C. Wendell
Mr. Wendell P. Weeks
Dr. Johnnetta B. Cole Ph.D.
Mr. Thomas H. Glocer
Mr. Steven F. Goldstone
Mr. William B. Harrison Jr.
Dr. Harry R. Jacobson
Dr. William N. Kelley M.D.
Ms. Rochelle B. Lazarus
Dr. Thomas E. Shenk Ph.D.
Contact Information
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ
908 423-1000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
